L-BLP25 vaccine extends survival in NSCLC

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1470, 2005-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The BLP25 cancer vaccine [Stimuvax] slows rising prostate specific antigen (PSA) levels in post-surgical prostate cancer patients

By  

Inpharma, Vol. 1, Iss. 1548, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

CAF chemotherapy extends survival with tamoxifen

By  

Inpharma, Vol. 1, Iss. 1474, 2005-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Cancer vaccine-GVAX: potential in NSCLC

By  

Inpharma, Vol. 1, Iss. 1434, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Docetaxel: impressive survival results in NSCLC

By  

Inpharma, Vol. 1, Iss. 1244, 2000-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Sipuleucel-T extends survival in metastatic prostate cancer

By  

Inpharma, Vol. 1, Iss. 1546, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite